Chapter 1: Introduction
1.1. Report Description
1.2. Key Benefits for Stakeholders
1.3. Key Market Segments
1.4. Research Methodology
1.4.1. Secondary Research
1.4.2. Primary Research
1.4.3. Analyst Tools and Models
Chapter 2: Executive Summary
2.1. Key Findings of the Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition and Scope
3.2. Key Findings
3.2.1. Top Winning Strategies
3.2.2. Top Investment Pockets
3.3. Market Share Analysis, 2020
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Rapid Growth of Geriatric Population
3.4.1.2. High Incidence of Neurodegenerative Disorders
3.4.1.3. Benefits of Smart Drugs
3.4.2. Restraint
3.4.2.1. Numerous Ethical Issues
3.4.3. Opportunity
3.4.3.1. Effective Strength of the Drugs
3.4.4. Impact Analyses
3.4. Covid-19 Impact Analysis
Chapter 4: Cognitive and Memory Enhancer Drugs Market, by Product
4.1. Overview
4.1.1. Market Size and Forecast
4.2. Aricept
4.2.1. Key Market Trends, Growth Factors, and Opportunities
4.2.2. Market Size and Forecast, by Region
4.2.3. Market Analysis, by Country
4.3. Exelon
4.3.1. Key Market Trends, Growth Factors, and Opportunities
4.3.2. Market Size and Forecast, by Region
4.3.3. Market Analysis, by Country
4.4. Namenda
4.4.1. Key Market Trends, Growth Factors, and Opportunities
4.4.2. Market Size and Forecast, by Region
4.4.3. Market Analysis, by Country
4.5. Razadyne
4.5.1. Key Market Trends, Growth Factors, and Opportunities
4.5.2. Market Size and Forecast, by Region
4.5.3. Market Analysis, by Country
4.6. Provigil
4.6.1. Key Market Trends, Growth Factors, and Opportunities
4.6.2. Market Size and Forecast, by Region
4.6.3. Market Analysis, by Country
4.7. Ritalin
4.7.1. Key Market Trends, Growth Factors, and Opportunities
4.7.2. Market Size and Forecast, by Region
4.7.3. Market Analysis, by Country
4.8. Adderall
4.8.1. Key Market Trends, Growth Factors, and Opportunities
4.8.2. Market Size and Forecast, by Region
4.8.3. Market Analysis, by Country
4.9. Others
4.9.1. Key Market Trends, Growth Factors, and Opportunities
4.9.2. Market Size and Forecast, by Region
4.9.3. Market Analysis, by Country
Chapter 5: Cognitive and Memory Enhancer Drugs Market, by Application
5.1. Overview
5.1.1. Market Size and Forecast
5.2. Disease Treatment
5.2.1. Market Size and Forecast, by Type
5.2.1.1. Developmental Conditions
5.2.1.1.1. Market Size and Forecast
5.2.1.2. Neurodegenerative Disorders
5.2.1.2.1. Market Size and Forecast
5.2.2. Market Size and Forecast, by Region
5.2.3. Market Analysis, by Country
5.3. Academic Performance
5.3.1. Market Size and Forecast, by Region
5.3.2. Market Analysis, by Country
5.4. Athletic Performance
5.4.1. Market Size and Forecast, by Region
5.4.2. Market Analysis, by Country
5.5. Others
5.5.1. Market Size and Forecast, by Region
5.5.2. Market Analysis, by Country
Chapter 6: Cognitive and Memory Enhancer Drugs Market, by Region
6.1. Overview
6.1.1. Market Size and Forecast
6.2. North America
6.2.1. Key Market Trends, Growth Factors, and Opportunities
6.2.2. North America Market Size and Forecast, by Country
6.2.2.1. U. S.
6.2.2.1.1. U. S. Market Size and Forecast, by Product
6.2.2.1.2. U. S. Market Size and Forecast, by Application
6.2.2.2. Canada
6.2.2.2.1. Canada Market Size and Forecast, by Product
6.2.2.2.2. Canada Market Size and Forecast, by Application
6.2.2.3. Mexico
6.2.2.3.1. Mexico Market Size and Forecast, by Product
6.2.2.3.2. Mexico Market Size and Forecast, by Application
6.2.3. North America Market Size and Forecast, by Product
6.2.4. North America Market Size and Forecast, by Application
6.3. Europe
6.3.1. Key Market Trends, Growth Factors, and Opportunities
6.3.2. Market Size and Forecast, by Country
6.3.2.1. Germany
6.3.2.1.1. Germany Market Size and Forecast, by Product
6.3.2.1.2. Germany Market Size and Forecast, by Application
6.3.2.2. France
6.3.2.2.1. France Market Size and Forecast, by Product
6.3.2.2.2. France Market Size and Forecast, by Application
6.3.2.3. Uk
6.3.2.3.1. Uk Market Size and Forecast, by Product
6.3.2.3.2. Uk Market Size and Forecast, by Application
6.3.2.4. Italy
6.3.2.4.1. Italy Market Size and Forecast, by Product
6.3.2.4.2. Italy Market Size and Forecast, by Application
6.3.2.5. Spain
6.3.2.5.1. Spain Market Size and Forecast, by Product
6.3.2.5.2. Spain Market Size and Forecast, by Application
6.3.2.6. Rest of Europe
6.3.2.6.1. Rest of Europe Market Size and Forecast, by Product
6.3.2.6.2. Rest of Europe Market Size and Forecast, by Application
6.3.3. Europe Market Size and Forecast, by Product
6.3.4. Europe Market Size and Forecast, by Application
6.4. Asia-Pacific
6.4.1. Key Market Trends, Growth Factors, and Opportunities
6.4.2. Market Size and Forecast, by Country
6.4.2.1. Japan
6.4.2.1.1. Japan Market Size and Forecast, by Product
6.4.2.1.2. Japan Market Size and Forecast, by Application
6.4.2.2. China
6.4.2.2.1. China Market Size and Forecast, by Product
6.4.2.2.2. China Market Size and Forecast, by Application
6.4.2.3. India
6.4.2.3.1. India Market Size and Forecast, by Product
6.4.2.3.2. India Market Size and Forecast, by Application
6.4.2.4. Australia
6.4.2.4.1. Australia Market Size and Forecast, by Product
6.4.2.4.2. Australia Market Size and Forecast, by Application
6.4.2.5. South Korea
6.4.2.5.1. South Korea Market Size and Forecast, by Product
6.4.2.5.2. South Korea Market Size and Forecast, by Application
6.4.2.5. Rest of Asia-Pacific
6.4.2.5.1. Rest of Asia-Pacific Market Size and Forecast, by Product
6.4.2.5.2. Rest of Asia-Pacific Market Size and Forecast, by Application
6.4.3. Asia-Pacific Market Size and Forecast, by Product
6.4.4. Asia-Pacific Market Size and Forecast, by Application
6.5. Lamea
6.5.1. Key Market Trends, Growth Factors, and Opportunities
6.5.2. Market Size and Forecast, by Country
6.5.2.1. Brazil
6.5.2.1.1. Brazil Market Size and Forecast, by Product
6.5.2.1.2. Brazil Market Size and Forecast, by Application
6.5.2.2. Saudi Arabia
6.5.2.2.1. Saudi Arabia Market Size and Forecast, by Product
6.5.2.2.2. Saudi Arabia Market Size and Forecast, by Application
6.5.2.3. South Africa
6.5.2.3.1. South Africa Market Size and Forecast, by Product
6.5.2.3.2. South Africa Market Size and Forecast, by Application
6.5.2.4. Rest of LAMEA
6.5.2.4.1. Rest of LAMEA Market Size and Forecast, by Product
6.5.2.4.2. Rest of LAMEA Market Size and Forecast, by Application
6.5.3. Lamea Market Size and Forecast, by Product
6.5.4. Lamea Market Size and Forecast, by Application
Chapter 7: Company Profile
7.1. Allergan plc.
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.1.6. Key Strategic Moves and Developments
7.2. Alternascript LLC
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.3. Biogen.
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Operating Business Segments
7.3.4. Product Portfolio
7.3.5. Business Performance
7.3. Ceretropic
7.3.1. Company Overview
7.3.2. Company Snapshot
7.3.3. Opreating Segmentt
7.3.4. Product Portfolio
7.4. Biogen.
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.4.6. Key Strategic Moves and Developments
7.5. Johnson & Johnson
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.5.6. Key Strategic Moves and Developments
7.6. Novartis International AG
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.6.6. Key Strategic Moves and Developments
7.7. Pfizer Inc.
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Torrent Pharmaceutical, Inc.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.9. Takeda Pharmaceutical Company Ltd.
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.9.6. Key Strategic Moves and Developments
7.10. Teva Pharmaceutical Industries Ltd. (Cephalon Inc.)
7.10.1. Company Overview
7.10.2. Company Snapshot
7.10.3. Operating Business Segments
7.10.4. Product Portfolio
7.10.5. Business Performance
List of Tables
List of Tables
Table 01. Global Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 02. Aricept Market, by Region, 2020–2030 ($Million)
Table 03. Exelon Market, by Region, 2020–2030 ($Million)
Table 04. Namenda Market, by Region, 2020–2030 ($Million)
Table 05. Razadyne Market, by Region, 2020–2030 ($Million)
Table 06. Provigil Market, by Region, 2020–2030 ($Million)
Table 07. Ritalin Market, by Region, 2020–2030 ($Million)
Table 08. Adderall Market, by Region, 2020–2030 ($Million)
Table 09. Others Market, by Region, 2020–2030 ($Million)
Table 10. Global Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 11. Effect of the Cognitive and Memory Enhancer Drugs Used for Disease Treatment
Table 12. Cognitive and Memory Enhancer Drugs Market for Disease Treatment, by Type, 2020–2030 ($Million)
Table 13. Cognitive and Memory Enhancer Drugs Market for Disease Treatment, by Region, 2020–2030 ($Million)
Table 14. Cognitive and Memory Enhancer Drugs Market for Academic Performance, by Region, 2020–2030 ($Million)
Table 15. Cognitive and Memory Enhancer Drugs Market for Athletic Performance, by Region, 2020–2030 ($Million)
Table 16. Cognitive and Memory Enhancer Drugs Market for Other Applications, by Region, 2020–2030 ($Million)
Table 17. Cognitive and Memory Enhancer Drugs Market, by Region, 2020–2030 ($Million)
Table 18. North America Cognitive and Memory Enhancer Drugs Market, by Country, 2020–2030 ($Million)
Table 19. U.S Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 20. U.S Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 21. Canada Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 22. Canada Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 23. Mexico Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 24. Mexico Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 25. North America Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 26. North America Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 28. Europe Cognitive and Memory Enhancer Drugs Market, by Country, 2020–2030 ($Million)
Table 29. Germany Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 30. Germany Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 31. France Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 32. France Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 33. Uk Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 34. Uk Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 35. Italy Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 36. Italy Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 37. Spain Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 38. Spain Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 39. Rest of Europe Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 40. Rest of Europe Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 41. Europe Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 42. Europe Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 43. Asia-Pacific Cognitive and Memory Enhancer Drugs Market, by Country, 2020–2030 ($Million)
Table 44. Japan Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 45. Japan Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 46. China Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 47. China Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 48. India Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 49. India Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 50. Australia Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 51. Australia Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Able 50. South Korea Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 51. South Korea Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 52. Rest of Asia-Pacific Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 53. Rest of Asia-Pacific Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 54. Asia-Pacific Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 55. Asia-Pacific Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 56. Lamea Cognitive and Memory Enhancer Drugs Market, by Country, 2020–2030 ($Million)
Table 57. Brazil Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 58. Brazil Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 59. Saudi Arabia Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 60. Saudi Arabia Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 61. South Africa Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 62. South Africa Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 63. Rest of LAMEA Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 64. Rest of LAMEA Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 65. Lamea Cognitive and Memory Enhancer Drugs Market, by Product, 2020–2030 ($Million)
Table 66. Lamea Cognitive and Memory Enhancer Drugs Market, by Application, 2020–2030 ($Million)
Table 67. Abbvie: Company Snapshot
Table 68. Abbvie: Operating Segments
Table 69. Abbvie: Product Portfolio
Table 70. Alternascript: Company Snapshot
Table 71. Alternascript: Operating Segments
Table 72. Alternascript: Product Portfolio
Table 73. Biogen: Company Snapshot
Table 74. Biogen: Product Portfolio
Table 75. Ceretropic: Company Snapshot
Table 76. Ceretropic: Operating Segments
Table 77. Ceretropic: Product Portfolio
Table 78. J&J: Company Snapshot
Table 79. J&J: Operating Segments
Table 80. J&J: Product Portfolio
Table 81. Novartis: Company Snapshot
Table 82. Novartis: Operating Segments
Table 83. Novartis: Product Portfolio
Table 84. Pfizer: Company Snapshot
Table 85. Pfizer: Operating Segments
Table 86. Pfizer: Product Portfolio
Table 87. Torrent: Company Snapshot
Table 88. Torrent: Product Portfolio
Table 89. Takeda: Company Snapshot
Table 90. Takeda: Operating Segments
Table 91. Takeda: Product Portfolio
Table 92. Teva: Company Snapshot
Table 93. Teva: Operating Segments
Table 94. Teva: Product Portfolio
List of Figures
Figure 01. Market Segmentation
Figure 02. Top Winning Strategies, by Year, 2015-2018*
Figure 03. Top Winning Strategies, by Development, 2015-2018* (%)
Figure 04. Top Winning Strategies, by Company, 2015-2018*
Figure 05. Top Investment Pockets
Figure 06. Market Share Analysis, 2020
Figure 07. Impact Analyses
Figure 08. Comparative Analysis of Aricept Market Revenue, by Country, 2020 & 2030 (%)
Figure 09. Comparative Analysis of Exelon Market Revenue, by Country, 2020 & 2030 (%)
Figure 10. Comparative Analysis of Namenda Market Revenue, by Country, 2020 & 2030 (%)
Figure 11. Comparative Analysis of Razadyne Market Revenue, by Country, 2020 & 2030 (%)
Figure 12. Comparative Analysis of Provigil Market Revenue, by Country, 2020 & 2030 (%)
Figure 13. Comparative Analysis of Ritalin Market Revenue, by Country, 2020 & 2030 (%)
Figure 14. Comparative Analysis of Adderall Market Revenue, by Country, 2020 & 2030 (%)
Figure 15. Comparative Analysis of Other Drugs Market Revenue, by Country, 2020 & 2030 (%)
Figure 16. Developmental Conditions Market, 2020-2023 ($ Million)
Figure 17. Neurodegenerative Disorders Market, 2020-2023 ($ Million)
Figure 18. Comparative Analysis of Disease Treatment Market Revenue, by Country, 2020 & 2030 (%)
Figure 19. Comparative Analysis of Cognitive and Memory Enhancer Drugs Market for Academic Performance Market, by Country, 2020 & 2030 (%)
Figure 20. Comparative Analysis of Cognitive and Memory Enhancer Drugs Market for Athletic Performance, by Country, 2020 & 2030 (%)
Figure 21. Comparative Analysis of Cognitive and Memory Enhancer Drugs Market for Other Applications, by Country, 2020 & 2030 (%)
Figure 22. Population Structure by Major Age Groups, Eu-28
Figure 23. Abbvie Inc: Net Sales, 2018–2020 ($ Million)
Figure 24. Abbvie Inc: Revenue Share by Segment, 2020 (%)
Figure 25. Abbvie Inc: Revenue Share Byregion, 2020 (%)
Figure 26. Biogen: Net Sales, 2018–2020 ($ Million)
Figure 27. Biogen: Revenue Share Byregion, 2020 (%)
Figure 28. J&J: Net Sales, 2018–2020 ($ Million)
Figure 29. J&J: Revenue Share by Segment, 2020 (%)
Figure 30. J&J: Revenue Share by Geography, 2020 (%)
Figure 31. Novartis: Net Sales, 2015–2017 ($ Million)
Figure 32. Novartis: Revenue Share by Segment, 2017 (%)
Figure 33. Novartis: Revenue Share by Geography, 2017 (%)
Figure 34. Pfizer: Net Sales, 2018–2020 ($ Million)
Figure 35. Pfizer: Revenue Share by Segment, 2020 (%)
Figure 36. Pfizer: Revenue Share by Geography, 2020 (%)
Figure 37Takeda: Net Sales, 2018–2020 ($ Million)
Figure 38. Takeda: Revenue Share by Segment, 2020 (%)
Figure 39. Takeda: Revenue Share by Geography, 2020 (%)
Figure 40. Teva: Net Sales, 2018–2020 ($ Million)
Figure 41. Teva: Revenue Share by Segment, 2020 (%)
Figure 42. Teva: Revenue Share by Geography, 2020 (%)